Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxcinod in Osteoarthritis of the Knee
NCT00504127Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Apr 2007
- Primary completion
- Dec 2008
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naproxcinod in osteoarthritis (OA) (4 arms), sponsored by Nicox S.A. Primary endpoint: Relief of Osteoarthritis Signs and Symptoms at 13 weeks. Started Apr 2007; status: completed.
02
Drugs
naproxcinod
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00504127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504127.